HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event:Oppenheime ...

Core Insights - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [4] - The CEO, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45 Annual Growth Conference from August 12-14, 2025 [1][2] - The company aims to introduce novel T cell therapies to the market and improve patient outcomes while preserving financial resources and focusing on operational excellence [4] Event Details - The fireside chat is scheduled for August 12, 2025, from 12:30 to 12:55 p.m. EDT at the InterContinental Boston Hotel [2] - During the conference, Dr. Vera and the management team will hold one-on-one meetings with registered investors to discuss the Multi-Antigen Recognizing (MAR) T cell platform and clinical developments [2] - Investors can access the event online through the company's Investor Relations website [3] Company Background - Marker Therapeutics was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its MAR-T cell products are well tolerated and show durable clinical responses [4] - The company benefits from non-dilutive funding from U.S. state and federal agencies supporting cancer research, which strengthens its unique T cell platform [4]